About Us

The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

GCAC CEO to Headline at Prohibition Partners LIVE on Tuesday, May 18th



Vancouver, British Columbia, Canada – TheNewswire - May 11, 2021Global Cannabis Applications Corp. (“GCAC” or the “Company) (CSE:APP) (OTC:FUAPF) (FSE:2FA) (CNSX:APP.CN) $APP $FUAP  a leading developer of innovative data technologies for the medical cannabis industry, today announced that CEO Brad Moore will be a featured panelist and presenter at Prohibition Partners LIVE, a renowned three-day virtual cannabis conference.

On May 18th at 6:45 AM PT, Moore, a former Fortune 500 executive and a proven operator of early-stage companies, will present on a four-person panel at Prohibition Partners LIVE’s day one morning event, “Is There a Doctor in the House? Patient Access to Medical Cannabis.” Moore will be joined by Mike Barnes, Chairman of the Medical Cannabis Clinicians Society, Dr. Rebecca Moore, a consulting psychiatrist with The Medical Cannabis Clinics, and Richard Hurley, a reporter for The British Medical Journal. The four speakers will discuss the challenges surrounding the use of medical cannabis by patients and physicians across the United Kingdom and Europe.

“GCAC is thrilled to participate in this year’s Prohibition Partners LIVE conference,” said Moore. “I look forward to discussing the current medical cannabis landscape across the United Kingdom – and, frankly, the rest of the world – and detailing how GCAC uses blockchain and other modern technologies to revolutionize access, efficiency, and most importantly- efficacy.”

Prohibition Partners operates the cannabis industry’s premier conferences with ~ 5,000 former global attendees and more than 500 acclaimed past speakers, such as Carlos Santana, Rock and Roll Hall of Famer and Co-Founder, Mirayo: Crispin Blunt, Member of UK Parliament, Conversative Party; Natalie Papillion, Board of Directors, The Last Prisoner Project; Dr. João Castel-Branco Goulão, National Drug Coordinator, Portugal; Bruce Linton, Founder of Canopy Growth; and Kelis, Grammy-Nominated American Singer and Songwriter and host of Netflix’s "Cooked with Cannabis." This year, Prohibition Partners LIVE is forecast to host approximately 800 attendees virtually worldwide.

 

GCAC is pleased to offer registrants a 20% discount on tickets for the three-day virtual conference, with the use of discount code GCAC20. To register, please visit: https://www.eventbrite.co.uk/e/prohibition-partners-live-may-18-20-2021-tickets-143105553563?aff=GCACPPL2021. In addition, Brad Moore will participate in Prohibition’s “Bespoke 30-Minute Master Class LIVE Q&A,” hosted by Swapcard – and will be featured on Prohibition’s “Sponsored Blog CEO Interview” on the conference’s website.

  


About Global Cannabis Applications Corp.

Global Cannabis Applications Corp. is a global leader in designing, developing, SaaS licensing, and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green and Efixii platforms are the world’s first end-to-end — from patient to regulator — medical cannabis data solutions. They use six core technologies: mobile applications, artificial intelligence, RegTech, smart databases, Ethereum blockchain, and GCAC smart rewards. These technologies transparently disclose cannabis chain-of-custody events, thereby enabling patients to provide crowd-sourced medical cannabis efficacy data. Driven by digital and cannabis industry experts, GCAC is focused on generating revenue from licensing its SaaS technology and acquiring high quality cannabis datasets that greatly improve patient outcomes.



For more Company information, please visit www.cannappscorp.com, or review its profiles on www.sedar.com and on the Canadian Securities Exchange’s website www.thecse.com.

 

Press Contact
Phone: +1 (800) 409-5679

Email: info@cannappscorp.com

 

Forward-Looking Information
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

 

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

Copyright (c) 2021 TheNewswire - All rights reserved.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.